Legend Biotech Corporation
Every calculator, already run for LEGN
Open the full toolkit →You have the numbers on LEGN. Get the argument.
A written report on which of these readings actually decide the outcome for Legend Biotech Corporation, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
13 analysts covering LEGNAnalyst Price Target Disagreement for Legend Biotech Corporation
Wall Street's bull case implies +268% from the current price; the bear case implies +30%. A 238% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for LEGN
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Legend Biotech Corporation
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer.…
LEGN — frequently asked
Is LEGN a buy right now?
Wall Street's consensus rating on Legend Biotech Corporation is Buy across 13 analysts, with a mean price target of $45.62 (+147% vs. the current $18.48). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is LEGN overvalued?
LEGN trades at — trailing earnings, against a DCF fair value of $4 per share. The current price implies 25% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is LEGN's next earnings date?
Legend Biotech Corporation is next scheduled to report earnings around Nov 11, 2026. A full LEGN research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Legend Biotech Corporation?
Analysts covering Legend Biotech Corporation (LEGN) range from a bear-case target of $24.00 to a bull-case high of $68.00, with a mean consensus target of $45.62 across 13 analysts. The spread of $44.00 (238% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Legend Biotech Corporation against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Legend Biotech Corporation
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full LEGN research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Legend Biotech Corporation, in minutes. 3 free reports included with every account — no credit card required.